Awaiting development: Guidance and quality standards

Showing 211 to 220 of 307

Guidance and quality standards awaiting development
Title	Type
Ravulizumab for preventing kidney events in people with chronic kidney disease at high risk after a cardiopulmonary bypass [ID6632]	Technology appraisal guidance
REGN5458 for treating relapsed or refractory multiple myeloma [ID6609]	Technology appraisal guidance
Remdesivir for treating COVID 19 [ID3808]	Technology appraisal guidance
Resmetirom for treating non-alcoholic steatohepatitis and liver fibrosis [TSID11905] [ID6529]	Technology appraisal guidance
Resminostat for maintenance treatment of advanced mycosis fungoides or Sezary syndrome [ID6478]	Technology appraisal guidance
Retatrutide for managing overweight and obesity [TSID12259]	Technology appraisal guidance
Retifanlimab with chemotherapy for previously untreated metastatic non-small-cell lung cancer [ID6436]	Technology appraisal guidance
Retifanlimab with platinum-based chemotherapy for treating inoperable, locally recurrent or metastatic squamous cell anal canal cancer untreated with systemic chemotherapy [ID6482]	Technology appraisal guidance
Ritlecitinib for treating non-segmental vitiligo in people 12 years and over [ID6584]	Technology appraisal guidance
Rivaroxaban for treating chronic heart failure [ID1462]	Technology appraisal guidance